Biopsy Sciences is a 2006 alum of the Larta-managed Commercialization Assistance Program (NIH-CAP) funded by the National Institutes of Health.

In another win for Larta Institute, CAP alum Biopsy Sciences, a Tucson, Arizona-based medical device company, sold the intellectual property and commercialization rights to its Bio-SEAL™ technology to Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company.

Biopsy Sciences was a participant in the 2006 “NIH-CAP”, a program funded by the National Institutes of Health (NIH) and developed and managed by Larta Institute to provide expert commercialization assistance and training to Phase II SBIR (Small Business Innovation Research) NIH- funded companies. The NIH-CAP, now in its fourth year, has worked with over 350 companies to accelerate early stage technology commercialization and success in the marketplace. The program is national in scope and provides high level strategy development and access to investors and corporate partners via Larta’s nationwide life sciences network.

Biopsy Sciences CEO, John Fisher successfully completed the ten-month NIH-CAP where he worked with Larta experts to further his proprietary Bio-SEAL technology, a biopsy tract sealant for safer and more accurate tissue biopsy procedures.. Biopsy Sciences CEO, John Fisher credits the program. "The education resources, lectures by leading experts in the field and mentorship program provided by the CAP program were instrumental in our company's success,” says Fisher, adding that NIH’s commitment to “help companies they fund transition from a start up to a profitable, strong company is well demonstrated in the CAP program.”  In addition, he adds, “the entire Larta team is very professional, well organized and great to work with."